Philip Bacchus

Philip Bacchus

Auto-generated profile, based on publicly available information

Philip Bacchus

Affiliations Lund University, Lund, Sweden, Swedish Armed Forces, Umeå, Sweden

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SHSebastian Havervall
Sebastian Havervall
UMUlrika Marking
Ulrika Marking
JSJulia Svensson
Julia Svensson
NGNina Greilert-Norin
Nina Greilert-Norin
PBPhilip Bacchus
Philip Bacchus
CTCharlotte Thålin
Charlotte Thålin
Mucosal IgA can provide immunity against respiratory viruses.1 Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) boosts mucosal IgA responses,2 and neutralizing IgA, including neutralizing IgA against the B.1.1.529 (omicron) variant of SARS-CoV-2, has been detected after infection with wild-type SARS-CoV-2.3 However, the potential role of mucosal IgA in protection against SARS-CoV-2 infection is still largely unknown.

22 January 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
KBKim Blom
Kim Blom
IGIlias Galanis
Ilias Galanis
PBPhilip Bacchus
Philip Bacchus
KSKlara Sondén
Klara Sondén
IBIoana Bujila
Ioana Bujila
JKJonas Klingstrom
Jonas Klingstrom
Acute SARS-CoV-2 infections are not always diagnosed; hence an unknown proportion of all infections are not documented. SARS-CoV-2 can induce spike and nucleocapsid protein specific IgG antibodies, which can be detected in seroprevalence studies to identify a previous infection. However, with the introduction of vaccines containing the spike protein it is no longer possible to use spike-IgG as a marker of infection. In many countries marketed vaccines do not include the nucleocapsid protein, allowing the use of nucleocapsid-specific IgG (N-IgG) as a specific marker for previous infection. Importantly however, not all SARS-CoV-2-infected individuals develop detectable N-IgG responses and there are reports of waning of N-IgG titers in previously infected individuals, complicating the use of N-IgG in seroprevalence studies. Here, our aim was to investigate N-IgG as a marker for previous infection. To this end we analyzed a well characterized cohort (n = 2,583; sampled in March, 2022), including 612 participants with a previously diagnosed and documented SARS-CoV-2-infection. We show that 75% (460/612) of the confirmed SARS-CoV-2-infected participants were N-IgG positive, and that the frequency of seropositivity was stable for at least 105 weeks after the latest documented SARS-CoV-2-infection. Among participants with no documented SARS-CoV-2-infection, 32.6% (642/1971) were N-IgG-positive, suggesting a previous infection. Assuming similar frequency of N-IgG-seronegative cases in previously diagnosed and undiagnosed individuals we further estimate that 214 of the 1329 undiagnosed and N-IgG-negative cases had been previously infected, indicating a total infection rate of 56.8% (1,468/2,583), clearly higher than the documented 23.7% rate of infection, in this cohort. In conclusion, our results suggest that while N-IgG is a good marker of previous SARS-CoV-2-infection the large proportion of previously infected N-IgG-negative individuals introduces a risk for underestimations of total level of previously infected individuals in a population. Accounting for this dark number of undiagnosable cases can provide better estimates of total level of infected individuals in a population.

1 October 2024 in Health Security
Verified
Journal Article
Open access
PBPhilip Bacchus
Philip Bacchus
WCWanda Christ
Wanda Christ
AFArian Frisell
Arian Frisell
NGNina Greilert-Norin
Nina Greilert-Norin
UMUlrika Marking
Ulrika Marking
RGRamona Groenheit
Ramona Groenheit
An important aspect of microbiological surveillance is the ability to access live viruses for microneutralization assays, which enables the study of viral characteristics and mechanisms in vitro and production of positive controls for diagnostic methods. During the COVID-19 pandemic, the Public Health Agency of Sweden established a protocol for the rapid collection of clinical samples and subsequent isolation of novel virus variants.